CR20190261A - Inhibidores de la tirosina quinasa de bruton - Google Patents
Inhibidores de la tirosina quinasa de brutonInfo
- Publication number
- CR20190261A CR20190261A CR20190261A CR20190261A CR20190261A CR 20190261 A CR20190261 A CR 20190261A CR 20190261 A CR20190261 A CR 20190261A CR 20190261 A CR20190261 A CR 20190261A CR 20190261 A CR20190261 A CR 20190261A
- Authority
- CR
- Costa Rica
- Prior art keywords
- independently
- alkyl
- hal
- fragment
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un nuevo compuesto de la Fórmula I: V2 V1 N N R1 R6 R4 R11 LR 3 n k Fórmula I o un estereoisómero, solvato o sal farmacéuticamente aceptable de este, en donde: 5 V1 es C o N, V2 es C (R2) o N, de manera que si V1 es C entonces V2 es N, si V1 es C entonces V2 es C (R2), o si V1 es N entonces V2 es C (R2); 10 cada n, k es independientemente 0, 1; cada R2, R11 es independientemente H, D, Hal, CN, NR¿R¿¿, C (O)NR¿R¿¿, alcoxi C1-C6; R3 es H, D, hidroxi, alquilo C (O)C1-C6, alquenilo C (O) C2-C6, alquinilo C (O) C2-C6, alquilo C1-C6; R4 es H, Hal, CN, CONR¿R¿¿, hidroxi, alquilo C1-C6, alcoxi C1-C6; L es CH2, NH, O o enlace químico; 15 R1 se selecciona del grupo de los fragmentos, que comprende: A1 A2 A4 A3 N O R5 R5 Fragmento 1, A1 A2 A4 A3 O A9 A8 A7 A6 A5 R5 Fragmento 2, 175 A1 A2 A4 A3 N H O A9 A8 A7 A6 A5 R5 Fragmento 3 cada A1, A2, A3, A4 es independientemente CH, N, CHal; cada A5, A6, A7, A8, A9 es independientemente C, CH o N; R5 es H, CN, Hal, CONR¿R¿¿, alquilo C1-C6, sin sustituir o sustituido por uno o más halógenos; cada R¿ y R¿¿ se selecciona independientemente a partir del grupo, que comprende H, alquilo C1-5 C6, cicloalquilo C1-C6, arilo; R6 se selecciona del grupo: N R7 O , N O R8 , N O R9, N O R10 ; cada R7, R8, R9, R10 es independientemente vinilo, metilacetilenilo; Hal es Cl, Br, I, F, 10 que tiene propiedades de inhibidor de la tirosina quinasa de Bruton (Btk), a composiciones farmacéuticas que contienen dichos compuestos, y su uso como productos farmacéuticos para el tratamiento de enfermedades y trastornos.The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662424041P | 2016-11-18 | 2016-11-18 | |
PCT/IB2017/057154 WO2018092047A1 (en) | 2016-11-18 | 2017-11-16 | Inhibitors of bruton's tyrosine kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20190261A true CR20190261A (es) | 2019-09-02 |
Family
ID=60574666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190261A CR20190261A (es) | 2016-11-18 | 2017-11-16 | Inhibidores de la tirosina quinasa de bruton |
Country Status (19)
Country | Link |
---|---|
US (1) | US20190352276A1 (es) |
EP (1) | EP3541811A1 (es) |
JP (1) | JP2019537611A (es) |
KR (1) | KR20190104516A (es) |
CN (1) | CN110177781A (es) |
AU (1) | AU2017362066A1 (es) |
BR (1) | BR112019009945A2 (es) |
CA (1) | CA3043297A1 (es) |
CL (1) | CL2019001330A1 (es) |
CR (1) | CR20190261A (es) |
EA (1) | EA201990902A1 (es) |
EC (1) | ECSP19043231A (es) |
JO (1) | JOP20190113A1 (es) |
MA (1) | MA45888A1 (es) |
MX (1) | MX2019005706A (es) |
PE (1) | PE20191082A1 (es) |
PH (1) | PH12019550083A1 (es) |
WO (1) | WO2018092047A1 (es) |
ZA (1) | ZA201903694B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10793566B2 (en) * | 2016-01-21 | 2020-10-06 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
WO2019013562A1 (ko) * | 2017-07-12 | 2019-01-17 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
KR102384924B1 (ko) | 2017-07-12 | 2022-04-08 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
AU2019314302A1 (en) | 2018-07-31 | 2021-01-28 | Loxo Oncology, Inc. | Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1H-pyrazole-4-carboxamide |
US11739090B2 (en) | 2019-09-26 | 2023-08-29 | Jumbo Drug Bank Co., Ltd. | Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors |
WO2022083741A1 (zh) * | 2020-10-23 | 2022-04-28 | 上海辉启生物医药科技有限公司 | 吡唑并吡啶类化合物或其盐及其制备方法和用途 |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2022228302A1 (en) * | 2021-04-25 | 2022-11-03 | Bionova Pharmaceuticals (Shanghai) Limited | Heteroaromatic carboxamide compounds and its use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL295053A (en) * | 2007-03-28 | 2022-09-01 | Pharmacyclics Llc | Broton tyrosine kinase inhibitors |
EP2464647B1 (en) * | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
AU2013299557B2 (en) * | 2012-08-10 | 2017-06-22 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors |
WO2015095099A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
AP2016009297A0 (en) * | 2014-02-03 | 2016-06-30 | Cadila Healthcare Ltd | Novel heterocyclic compounds |
AU2015296215A1 (en) * | 2014-08-01 | 2017-03-23 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
JP6950897B2 (ja) * | 2016-01-21 | 2021-10-13 | ジーボ・バイオポーラー・チャンシェン・ファーマシューティカル・カンパニー・リミテッドZibo Biopolar Changsheng Pharmaceutical Co. Ltd. | ブルトン型チロシンキナーゼ阻害剤 |
WO2017156495A1 (en) * | 2016-03-11 | 2017-09-14 | Corvus Pharmaceuticals, Inc. | Compounds and methods for modulating bruton's tyrosine kinase |
-
2017
- 2017-06-16 JO JOP/2019/0113A patent/JOP20190113A1/ar unknown
- 2017-11-16 AU AU2017362066A patent/AU2017362066A1/en not_active Abandoned
- 2017-11-16 MA MA45888A patent/MA45888A1/fr unknown
- 2017-11-16 WO PCT/IB2017/057154 patent/WO2018092047A1/en active Application Filing
- 2017-11-16 MX MX2019005706A patent/MX2019005706A/es unknown
- 2017-11-16 JP JP2019525970A patent/JP2019537611A/ja active Pending
- 2017-11-16 EP EP17809035.3A patent/EP3541811A1/en not_active Withdrawn
- 2017-11-16 CN CN201780081869.5A patent/CN110177781A/zh active Pending
- 2017-11-16 US US16/461,537 patent/US20190352276A1/en not_active Abandoned
- 2017-11-16 CA CA3043297A patent/CA3043297A1/en not_active Abandoned
- 2017-11-16 BR BR112019009945A patent/BR112019009945A2/pt not_active Application Discontinuation
- 2017-11-16 PE PE2019001009A patent/PE20191082A1/es unknown
- 2017-11-16 CR CR20190261A patent/CR20190261A/es unknown
- 2017-11-16 KR KR1020197016234A patent/KR20190104516A/ko unknown
-
2019
- 2019-05-07 EA EA201990902A patent/EA201990902A1/ru unknown
- 2019-05-10 PH PH12019550083A patent/PH12019550083A1/en unknown
- 2019-05-16 CL CL2019001330A patent/CL2019001330A1/es unknown
- 2019-06-10 ZA ZA2019/03694A patent/ZA201903694B/en unknown
- 2019-06-17 EC ECSENADI201943231A patent/ECSP19043231A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20191082A1 (es) | 2019-08-20 |
JP2019537611A (ja) | 2019-12-26 |
ECSP19043231A (es) | 2019-06-30 |
EP3541811A1 (en) | 2019-09-25 |
US20190352276A1 (en) | 2019-11-21 |
WO2018092047A1 (en) | 2018-05-24 |
AU2017362066A1 (en) | 2019-05-30 |
MX2019005706A (es) | 2019-07-08 |
JOP20190113A1 (ar) | 2019-05-15 |
CL2019001330A1 (es) | 2019-09-27 |
EA201990902A1 (ru) | 2019-11-29 |
BR112019009945A2 (pt) | 2019-08-13 |
CA3043297A1 (en) | 2018-05-24 |
KR20190104516A (ko) | 2019-09-10 |
MA45888A1 (fr) | 2020-06-30 |
PH12019550083A1 (en) | 2020-03-09 |
ZA201903694B (en) | 2021-04-28 |
CN110177781A (zh) | 2019-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20190261A (es) | Inhibidores de la tirosina quinasa de bruton | |
CL2020000427A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
AR109348A1 (es) | Sulfonilureas y compuestos relacionados y sus usos | |
CO2019008531A2 (es) | Análogos de atazanavir (atv) para tratar infecciones por vih. | |
AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
AR059905A1 (es) | Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto | |
AR068511A1 (es) | Tetrahidro[1,4'] bipiridinil-2'-onas sustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central | |
BR112016019462B8 (pt) | Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase | |
CL2019002919A1 (es) | Compuestos inhibidores vmat2 y composiciones relacionadas. | |
AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
PE20200756A1 (es) | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica | |
AR088810A1 (es) | Moduladores del receptor mas acoplado a la proteina g utiles en el tratamiento de trastornos cardiovasculares y composiciones farmaceuticas que los contienen | |
AR092809A1 (es) | 3,5-diaminopirazol como inhibidor de quinasa | |
AR061015A1 (es) | Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto | |
PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
AR086029A1 (es) | Compuesto derivado de fenil-isoxazol, metodo para prepararlo, composiciones y combinaciones que lo comprende, su uso para preparar una composicion farmaceutica para el tratamiento o la prevencion de infecciones virales y metodo para prevenir tales tratamientos o prevenciones | |
PE20211456A1 (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado |